Source:http://linkedlifedata.com/resource/pubmed/id/20307650
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2010-5-24
|
pubmed:abstractText |
Initiation and progression of Parkinson's disease seem to be linked to oxidative stress, closely related to decreased mitochondrial functions and ubiquitin proteasome system dysfunction. To date, L-Dopa is the most effective medication , although long-term treatment can enhance oxidative stress and accelerate the degenerative process of residual cells. Therefore the inhibition of oxidation of L-Dopa/dopamine and the inhibition of reactive oxygen species formation are important strategies for neuroprotective therapy. Recently, several dual acting drugs, in which L-Dopa/dopamine are covalently linked to antioxidant molecules, were shown to induce sustained delivery of both L-Dopa/dopamine in rat plasma and striatum, suggesting that these compounds might be proposed as useful agents against Parkinson's disease. Here, by analyzing GSH levels and heme oxygenase-1 expression, we investigated in primary mesencephalic neuron cultures and in newborn mice the effects of the treatment with Ac-Met-LD-OMe. Moreover, by using proteasome inhibitor-treated mice as Parkinson's disease animal model, we demonstrated the beneficial effects of the systemic administration of this novel codrug.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Glutathione,
http://linkedlifedata.com/resource/pubmed/chemical/Heme Oxygenase-1,
http://linkedlifedata.com/resource/pubmed/chemical/Levodopa,
http://linkedlifedata.com/resource/pubmed/chemical/levodopa methyl ester
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1873-4596
|
pubmed:author | |
pubmed:copyrightInfo |
(c) 2010 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
31-9
|
pubmed:meshHeading |
pubmed-meshheading:20307650-Animals,
pubmed-meshheading:20307650-Animals, Newborn,
pubmed-meshheading:20307650-Antiparkinson Agents,
pubmed-meshheading:20307650-Apoptosis,
pubmed-meshheading:20307650-Cells, Cultured,
pubmed-meshheading:20307650-Cytoprotection,
pubmed-meshheading:20307650-Female,
pubmed-meshheading:20307650-Glutathione,
pubmed-meshheading:20307650-Heme Oxygenase-1,
pubmed-meshheading:20307650-Levodopa,
pubmed-meshheading:20307650-Male,
pubmed-meshheading:20307650-Mesencephalon,
pubmed-meshheading:20307650-Mice,
pubmed-meshheading:20307650-Mice, Inbred C57BL,
pubmed-meshheading:20307650-Neurons,
pubmed-meshheading:20307650-Oxidative Stress,
pubmed-meshheading:20307650-Parkinson Disease,
pubmed-meshheading:20307650-Pregnancy
|
pubmed:year |
2010
|
pubmed:articleTitle |
N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
|
pubmed:affiliation |
Dipartimento Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Università di Perugia, Via del Giochetto, 06124, Perugia, Italia. aminelli@unipg.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|